一种IL-12部分激动剂维持了内淋巴细胞激活,并对全身IL-12疗法进行排毒
Ievgen Koliesnik1, Michael Totagrande1, Bhargavi Jayaraman1
1Synthekine Inc., Menlo Park, CA, USA.
Cell reports
|December 20, 2025
概括
工程介素-12 (IL-12) 疗法 (STK-026) 通过激活T细胞来增强抗瘤免疫力,同时避免有毒NK细胞过活化. 这种新型免疫疗法在临床前模型中显示出有效性和更广泛的治疗窗口.
科学领域:
- 免疫学和癌症治疗疗法
背景情况:
- 互乐金-12 (IL-12) 是一种强大的免疫疗法细胞因子,具有显著的临床前抗瘤活性.
- 由于严重的毒性,包括NK细胞过活化和细胞因子风暴,阻碍了IL-12的临床应用.
- 野生型IL-12导致NK细胞过度活化,细胞因子风暴,并随后NK细胞耗尽在小鼠模型.
研究的目的:
- 设计一种IL-12变体 (STK-026),在减轻IL-12诱导毒性时保持抗瘤功效.
- 在临床前癌症模型和非人类灵长类动物中研究STK-026的治疗潜力.
主要方法:
- 设计了一种IL-12-Fc融合蛋白 (STK-026),具有减弱的IL-12受体β1 (IL-12Rβ1) 结合.
- 在小鼠瘤模型中评估STK-026,用于免疫细胞激活,透和瘤控制.
- 在非人类灵长类动物中评估STK-026的安全性和免疫效应.
主要成果:
- STK-026选择性地向激活的T细胞,避免NK细胞过度活化和细胞因子风暴.
- STK-026促进持续的T细胞激活,干扰素-生产,以及TILs,巨细胞和NK细胞的透.
- STK-026在小鼠中显示出显著的瘤控制,包括"冷"瘤,并与抗PD-1疗法协同作用.
- 与野生型IL-12相比,STK-026在非人类灵长类动物中显示出更好的安全概况.
结论:
- STK-026代表了一种基于IL-12的新型免疫疗法,具有增强的抗瘤疗效和显著改善的治疗指数.
- 这种工程性细胞因子避免了与传统IL-12相关的急性毒性,为癌症治疗提供了一个有前途的新途径.
关键词:
CP: 免疫学 免疫学在IL-12中,IL-12是最重要的.它们是IL-12Rβ1的基因.它们是IL-12Rβ2的基因.在 NK 细胞中,NK 细胞是 NK 细胞.在STK-02626中使用.细胞因子细胞因子免疫疗法 免疫疗法介质蛋白12 介质蛋白12这种细胞是t细胞.更多相关视频
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
1.6K
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
15.2K
相关概念视频
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:24T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K